🇺🇸 FDA
Patent

US 10519423

High efficiency reprogramming of fibroblasts into cardiomyocytes

granted A61KA61K31/713A61K38/1709

Quick answer

US patent 10519423 (High efficiency reprogramming of fibroblasts into cardiomyocytes) held by The Regents of the University of Colorado, a Body Corporate expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61K, A61K31/713, A61K38/1709, A61K45/06, A61K48/00